Thursday, April 25, 2024, Washington, DC, 12:15 PM – 1:45 PM Eastern Time

What I Tell My Patients: Integrating New Research Information into Current Clinical Care

A Complimentary NCPD Hybrid Symposium Series Held During the 49th Annual ONS Congress

Optimal Implementation of Antibody-Drug Conjugates

 
Location
Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Program Schedule — Eastern Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — NCPD Lunch Meeting

Meeting Room
Independence Ballroom (Meeting Level 4)

This event will also be webcast live.
Please see Registration tab for details.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.  
 
Faculty
Jamie Carroll, APRN, MSN, CNP
Assistant Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Kelly EH Goodwin, MSN, RN, ANP-BC
Thoracic Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Erika Hamilton, MD
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee


Hope S Rugo, MD
Professor of Medicine
Winterhof Family Professor of Breast Cancer
Director, Breast Oncology
and Clinical Trials Education
Medical Director, Cancer Infusion Services
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24-28, 2024 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Eastern Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — NCPD Lunch Meeting

What I Tell My Patients About ...

The Rationale for Antibody-Drug Conjugates (ADCs) as Cancer Treatment

  • Specificity of monoclonal antibodies and ability of these drugs to target cancer cells while avoiding normal tissues
  • Rationale for conjugating monoclonal antibodies with cytotoxic drugs; theoretical improvement of chemotherapy efficacy while reducing systemic exposure and toxicity
  • Structural components of commercially available and investigational ADCs, such as antibodies, linkers and cytotoxic payloads
  • Direct mechanism of antitumor activity of ADCs
  • Other means by which ADCs can elicit an antitumor effect, such as bystander killing, antibody-dependent cellular toxicity and complement-dependent cytotoxicity

The Current and Future Role of ADCs in Cancer Therapy

  • FDA-approved indications for ADCs for various tumor types
  • Other promising ADCs in clinical development as anticancer therapy
  • Counseling patients regarding reasonable expectations about ADC efficacy and tolerability; customizing communication strategies based on individual preferences, educational background, cultural and linguistic background, et cetera
  • Suitability of ADCs for various patient populations, including those who are older or frail and those with preexisting comorbidities

Practical Considerations with ADCs

  • Optimal timing for initiation of approved ADCs or consideration of a clinical trial evaluating one of these agents
  • Mode of administration, dose and schedule of various ADCs
  • Recommended premedications for patients about to begin therapy with an ADC
  • Known drug-drug interactions between ADCs and other classes of agents

Cytopenias Associated with ADCs

  • Educating patients regarding the capacity of ADCs to cause acute chemotherapy-like side effects
  • Incidence and severity of neutropenia, thrombocytopenia and anemia with approved and investigational ADCs
  • Appropriate monitoring of complete blood counts during therapy
  • Thresholds for dose modification, treatment interruption or treatment discontinuation for patients experiencing cytopenias

The Incidence and Management of Interstitial Lung Disease (ILD) with ADCs

  • Pathophysiology of ILD associated with ADCs; baseline risk factors for the development of ILD
  • Rates, severity and timing of ILD in clinical trials of various ADCs
  • Appropriate workup for patients suspected of experiencing therapy-related ILD; strategies to distinguish drug-related pulmonary toxicity from other potential causes
  • Guidelines for treatment modifications and discontinuation for patients experiencing complications from ILD; indications for restarting ADC therapy after resolution of symptoms
  • Utility of other supportive care measures for patients experiencing ILD, such as corticosteroids and oxygen supplementation

The Potential for Mucositis/Stomatitis with Certain ADCs

  • Incidence and severity of mucositis/stomatitis with various approved and investigational ADCs
  • Educating patients about the importance of oral hygiene during treatment with ADCs known to cause mucositis/stomatitis
  • Role of prescription steroid mouthwash or homemade mouth rinses, prophylactic antibiotics/antifungals and pain medications for patients at risk for or experiencing mucositis/stomatitis
  • Dietary recommendations for patients experiencing mucositis/stomatitis; utility of meal replacement shakes or protein powders for those not receiving adequate nutrition

Gastrointestinal Side Effects of ADCs

  • Rates of various gastrointestinal issues, such as nausea/vomiting, diarrhea, decreased appetite and constipation, among patients receiving ADC therapy
  • Role of prophylactic antiemetics and/or antidiarrheals for patients about to begin treatment with an ADC
  • Educating patients regarding strategies to maintain proper nutrition during treatment, such as eating small, frequent meals, avoiding spicy, greasy or fried foods, maintaining adequate hydration and eating cold and/or tart foods
  • Role of complementary therapies such as acupuncture in managing gastrointestinal side effects of ADCs

Rare Cardiac Toxicities with HER2-Targeted ADCs

  • Pathophysiology of the cardiotoxicity associated with anti-HER2 therapies, including ADCs
  • Incidence of left ventricular dysfunction noted with HER2-targeted ADCs in clinical trial experiences
  • Appropriate monitoring of left ventricular ejection fraction (LVEF) at baseline and during treatment with HER2-targeted ADCs
  • Threshold for treatment interruption for patients experiencing LVEF decrease; indications for restarting HER2-targeted ADC therapy after recovery
  • Role of interdisciplinary coordination with cardiologists when monitoring for and managing cardiac toxicities associated with HER2-targeted ADCs

Ocular Toxicities of ADCs

  • Pathophysiology of ocular adverse events associated with certain ADCs; spectrum, incidence and severity of ocular toxicities with different agents
  • Optimal patient counseling and education regarding signs of ocular toxicity and the importance of early reporting of symptoms
  • Guidelines for treatment modification for patients experiencing ocular complications of ADCs
  • Utility of other prophylactic and supportive care measures to mitigate and/or manage ocular toxicities
  • Importance of interdisciplinary coordination with eye-care professionals in the identification and management of treatment-related ocular events

Other Toxicities Associated with ADCs

  • Incidence and management of peripheral neuropathy associated with various ADCs
  • Strategies to mitigate the potential psychosocial ramifications of visible side effects of ADC treatment, such as alopecia
  • Spectrum of other toxicities associated with 1 or more ADCs used in the treatment of cancer, such as fatigue, cutaneous reactions, hemorrhage, effusion/edema and hyperglycemia
  • Collaborative role of oncology nurses in comprehensive biopsychosocial care for patients with cancer; capacity to optimize clinical and quality-of-life outcomes with anticancer therapies, including ADCs

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider the scientific justification for antibody-drug conjugates (ADCs) as a therapeutic approach for various cancers, and recall the targets, structural components and mechanisms of activity of different clinically available and investigational ADCs.
  • Appraise research data with novel ADCs for various cancers, and consider the current and future role of these approaches in routine clinical care.
  • Appreciate the pathophysiology and severity of common and rare toxicities associated with various ADCs in the treatment of different cancers.
  • Understand the incidence of different toxicities observed in pivotal trials evaluating novel ADCs demonstrating efficacy in the management of various tumor types, and educate patients about to start therapy with these approaches about the potential for these adverse events and what to do if they are suspected.
  • Recall strategies commonly employed to identify, manage and mitigate toxicities in patients receiving ADCs for cancer, and use this information to appropriately intervene when side effects are suspected or diagnosed.
  • Understand the role of multidisciplinary specialists such as cardiologists, ophthalmologists and other medical professionals in the diagnosis and management of various ADC-associated toxicities, and effectively educate patients about the potential need for and importance of specialty referral.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Goodwin — No relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms CarrollSpeakers Bureaus: AstraZeneca Pharmaceuticals LP, Lilly, Novartis. Dr HamiltonConsulting Agreements — Payment Made to Institution: Accutar Biotechnology Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Ellipses Pharma, Entos Pharmaceuticals, Fosun Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, Jazz Pharmaceuticals Inc, Lilly, Mersana Therapeutics Inc, MphaR, Novartis, Olema Oncology, Orum Therapeutics, Pfizer Inc, Stemline Therapeutics Inc, Theratechnologies, Tubulis, Zentalis Pharmaceuticals; Contracted Research — Payment Made to Institution: AbbVie Inc, Accutar Biotechnology Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, Aravive Inc, ArQule Inc, Artios, Arvinas, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, BeiGene Ltd, Black Diamond Therapeutics Inc, Bliss Biopharmaceutical, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Context Therapeutics, Cullinan Oncology, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Duality Biologics, eFFECTOR Therapeutics Inc, Ellipses Pharma, Elucida Oncology Inc, EMD Serono Inc, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Inspirna, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, K-Group Beta, Kind Pharmaceuticals LLC, Leap Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Mersana Therapeutics Inc, Merus, Molecular Templates, Myriad Genetic Laboratories Inc, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, Oncothyreon, ORIC Pharmaceuticals, Orinove Inc, Orum Therapeutics, Pfizer Inc, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Prelude Therapeutics, ProfoundBio, Radius Health Inc, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Repertoire Immune Medicines, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tolmar, Transcenta, Treadwell Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks Inc; Nonrelevant Financial Relationship: Verascity Science. Dr RugoConsulting Agreements: Daiichi Sankyo Inc, Eisai Inc, Napo Pharmaceuticals Inc, Viatris; Contracted Research: Ambrx, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Stemline Therapeutics Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence Ballroom (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2024 ONS Congress and is connected to the Walter E Washington Convention Center by an underground concourse.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ONS Congress.

IN-PERSON Registration for nurses and other healthcare providers

I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.